A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

ID 153865
Author(s) Kussebi, Fatimah; Karamloo, Fariba; Rhyner, Claudio; Schmid-Grendelmeier, Peter; Salagianni, Maria; Mannhart, Christian; Akdis, Mübeccel; Soldatova, Lyudmilla; Markovic-Housley, Zora; Von Beust, Barbara R; Kündig, Thomas; Kemeny, David M; Blaser, Kurt; Crameri, Reto; Akdis, Cezmi A
Author(s) at UniBasel Schirmer, Tilman ; Housley-Markovic, Zora ;
Year 2005
Title A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy
Journal The journal of allergy and clinical immunology
Volume 115
Number 2
Pages / Article-Number 323-9
Keywords specific immunotherapy, allergy, bee venom, T cells, IgE

Background: Specific immunotherapy is a common treatment of allergic diseases and could potentially be applied to other immunologic disorders. Despite its use in clinical practice, more defined and safer allergy vaccine preparations are required. Differences between epitopes of IgE that recognize the 3-dimensional structure of allergens and T cells that recognize linear amino acid sequences provide a suitable tool for novel vaccine development for specific immunotherapy. Objective: The aim of the study was to delete B-cell epitopes and prevent IgE crosslinking, but to preserve T-cell epitopes by fusion of 2 major allergens of bee venom because of a change in the conformation. Methods: By genetic engineering, we produced a fusion protein composed of the 2 major bee venom allergens: phospholipase A(2) (Api m 1) and hyaluronidase (Api m 2). Results: The Api m [1/2] fusion protein induced T-cell proliferation and both T(H)1-type and T(H)2-type cytokine responses. In contrast, IgE reactivity was abolished, and profoundly reduced basophil degranulation and type 1 skin test reactivity was observed. Pretreatment of mice with Api m [1/2] fusion protein significantly suppressed the development of specific IgE as well as other antibody isotypes after immunization with the native allergen. Conclusion: The novel fusion protein of 2 major allergens bypasses IgE binding and mast cell/basophil IgE Fc epsilon RI crosslinking and protects from IgE development.